Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation
Abstract ERBB2 mutations are found in about 2% of patients with non‐small cell lung cancer (NSCLC). A recent study reported that pyrotinib (an irreversible pan ErbB inhibitor) had superior antitumor effect compared to other tyrosine kinase inhibitor therapies in patients with ERBB2 mutations. Bone m...
Main Authors: | Yanyan Wu, Jun Ni, Xiaoyan Chang, Xiaotong Zhang, Li Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-07-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13480 |
Similar Items
-
Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study
by: Ding K, et al.
Published: (2021-01-01) -
Non‐small‐cell lung cancer with ERBB2 mutation in non‐tyrosine kinase domain benefits from pyrotinib: A case report
by: Jun Ni, et al.
Published: (2021-04-01) -
Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma
by: Zhongben Tang, et al.
Published: (2021-03-01) -
Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults
by: Liu Y, et al.
Published: (2021-06-01) -
Clinical and molecular characteristics of Chinese non‐small cell lung cancer patients with ERBB2 transmembrane domain mutations
by: Yun Fan, et al.
Published: (2020-08-01)